Is Semaglutide with BPC-157 legal in Australia?

An approved drug with a 14.9% weight loss result paired with a peptide that FDA staff reviewed in 2026 and found had no adequate human data. The combination has never been tested. The stated reason for the pairing, that BPC-157 protects the gut or preserves muscle during rapid weight loss, has no trial behind it in any species for either claim.

This pairing exists because of a real problem. Rapid weight loss on a GLP-1 costs lean mass along with fat, and the gastrointestinal side effects are the main reason people stop.

Mechanism: Semaglutide acts at the GLP-1 receptor to reduce appetite and slow gastric emptying. BPC-157 is described in rodent work as promoting angiogenesis, upregulating growth hormone receptor expression and reducing inflammatory cytokines.

Regulatory history: Semaglutide is approved. BPC-157 is not approved and was reviewed by FDA staff in July 2026, who found no adequate human data and mislabelled products in the market. The combination has never been evaluated.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Semaglutide with BPC-157 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.